ArticleOncology letters2025
Overexpression of STOML1 is associated with good prognosis in nasopharyngeal carcinoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a prevalent head and neck malignancy characterized by high recurrence rate, adversely affecting patient prognosis. The present study aimed to identify key genes and mechanisms affecting NPC prognosis using DNA microarray, bioinformatics analysis and clinical data integration. The gene expression profile of patients with NPC with favorable (n=12) and unfavorable (n=8) prognoses was assessed using cDNA profiling. Bioinformatics analysis was performed to identify key prognostic factors, whilst immunohistochemistry assays were performed to evaluate the association between gene-protein expression in 107 NPC samples. The prognostic significance was assessed using Cox regression analysis, Kaplan-Meier curves, log-rank tests and receiver operating characteristic (ROC) analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to assess the underlying mechanisms. cDNA profiling identified six genes, including stomatin like 1 (STOML1), as significant prognostic factors. The Kaplan-Meier Plotter and The Cancer Genome Atlas database indicated that the mRNA expression levels of STOML1 were significantly associated (P<0.05) with head and neck squamous cell carcinoma prognosis. In addition, tissue microarray analysis revealed that high protein expression levels of STOML1 were significantly associated (P<0.05) with improved overall survival (OS) and disease-free survival (DFS). Furthermore, univariate and multivariate Cox analyses demonstrated that STOML1 expression is an independent prognostic factor for OS and DFS. ROC analysis also revealed improved predictive accuracy for 5-year OS when combining STOML1 expression with tumor-node-metastasis (TNM) staging [area under the curve (AUC)=0.874; P<0.001], compared with TNM staging alone (AUC=0.715; P=0.043) and STOML1 expression alone (AUC=0.774; P=0.010). Finally, GO and KEGG analyses demonstrated that the identified genes were mainly involved in pathways associated with apoptosis and cancer progression. Overall, the results of the present study suggested that STOML1 could serve a crucial role in NPC progression and could therefore serve as a valuable biomarker for NPC diagnosis and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.